Tag - ARDS

Markets

Maxim cuts Aridis Pharma to hold

Maxim Group downgraded Aridis Pharmaceuticals (NASDAQ:ARDS) to “hold” from “buy” and removed its price target, citing capital concerns and key clinical programs. The stock closed at $2.19 on Aug. 15. In a 10-Q report...

August 16, 2022

Developments

Aridis Pharma enrolls first COVID-19 patient in ongoing Phase 3 trial

Aridis Pharmaceuticals (NASDAQ:ARDS) enrolled the first COVID-19 patient in its ongoing Phase 3 trial of AR-301 for ventilator-associated pneumonia. Initiated in the first quarter of 2019, the Phase 3 study will assess...

May 4, 2020

Developments

Aridis Pharma gets EMA orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF). AR-501 is an inhaled...

July 19, 2019

Tag - ARDS

Maxim cuts Aridis Pharma to hold

Aridis Pharma enrolls first COVID-19 patient in ongoing Phase 3 trial

Aridis Pharma gets EMA orphan drug designation for CF drug

General

More